Keech, Anthony

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Giugliano, R. P., Pedersen, T. R., Saver, J. L., Sever, P. S., Keech, A. C., Bohula, E. A., Murphy, S. A., Wasserman, S. M., Honarpour, N., Wang, H., et al. (2020) · Stroke

Lipoproteins and Cardiovascular HealthAcute Ischemic Stroke Management

Cited by 184

Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis

Preiss, D., Tikkanen, M. J., Welsh, P., Ford, I., Lovato, L. C., Elam, M. B., LaRosa, J. C., DeMicco, D. A., Colhoun, H. M., Goldenberg, I., et al. (2012) · JAMA

Pancreatitis Pathology and TreatmentLipoproteins and Cardiovascular Health

Cited by 181

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

Sabatine, M. S., Giugliano, R. P., Keech, A., Honarpour, N., Wang, H., Liu, T., Wasserman, S. M., Scott, R., Sever, P. S., & Pedersen, T. R. (2016) · American Heart Journal

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 176

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis

Reith, C., Preiss, D., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., et al. (2024) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 161

Effect of pravastatin in people with diabetes and chronic kidney disease

Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, J., Isles, C., Furberg, C., et al. (2005) · Journal of the American Society of Nephrology

Lipoproteins and Cardiovascular HealthChronic Kidney Disease and Diabetes

Cited by 159

Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial

Martin, S. S., Giugliano, R. P., Murphy, S. A., Wasserman, S. M., Stein, E. A., Ceška, R., López-Miranda, J., Georgiev, B., Lorenzatti, A. J., Tikkanen, M. J., et al. (2018) · JAMA Cardiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 150

Statins for people at low risk of cardiovascular disease – Authors' reply

Mihaylova, B., Emberson, J., Keech, A., Collins, R., & Baigent, C. (2012) · The Lancet

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 146

Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

Burgess, D. C., Hunt, D., Li, L., Zannino, D., Williamson, E., Davis, T. M. E., Laakso, M., Kesaniemi, Y. A., Zhang, J., Sy, R. W., et al. (2010) · European Heart Journal

Acute Myocardial Infarction ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 119

Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment

Ting, R.-D., Keech, A. C., Drury, P. L., Donoghoe, M. W., Hedley, J., Jenkins, A. J., Davis, T. M. E., Lehto, S., Celermajer, D., Simes, R. J., et al. (2012) · Diabetes Care

Chronic Kidney Disease and DiabetesLipoproteins and Cardiovascular Health

Cited by 119

Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes

on behalf of the FIELD study investigators, Taskinen, M.-R., Barter, P. J., Ehnholm, C., Sullivan, D. R., Mann, K., Simes, J., Best, J. D., Hamwood, S., & Keech, A. C. (2010) · Diabetologia

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 94

Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study

KEECH, A., COLLINS, R., MACMAHON, S., ARMITAGE, J., LAWSON, A., WALLENDSZUS, K., FATEMIAN, M., KEARNEY, E., LYON, V., MINDELL, J., et al. (1994) · European Heart Journal

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 90

Long-term glycemic variability and vascular complications in type 2 diabetes: post hoc analysis of the field study

Scott, E. S., Januszewski, A. S., O’Connell, R., Fulcher, G., Scott, R., Kesaniemi, A., Wu, L., Colagiuri, S., Keech, A., & Jenkins, A. J. (2020) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 70

Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus

Hiukka, A., Leinonen, E., Jauhiainen, M., Sundvall, J., Ehnholm, C., Keech, A. C., & Taskinen, M. R. (2007) · Diabetologia

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 68

Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate

Taskinen, M.-R., Sullivan, D. R., Ehnholm, C., Whiting, M., Zannino, D., Simes, R. J., Keech, A. C., & Barter, P. J. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipoproteins and Cardiovascular HealthFolate and B Vitamins Research

Cited by 63

Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

on behalf of the FIELD Study Investigators, d’Emden, M. C., Jenkins, A. J., Li, L., Zannino, D., Mann, K. P., Best, J. D., Stuckey, B. G. A., Park, K., Saltevo, J., et al. (2014) · Diabetologia

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 49

We-S15:2 Effects of long-term fenofibrate therapy on cardiovascular events among 9795 people with type 2 diabetes mellitus: The field study, a randomised controlled trial

Keech, A., & Field Study Investigators (2006) · Atherosclerosis Supplements

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 28

No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab

Korthauer, L. E., Giugliano, R. P., Guo, J., Sabatine, M. S., Sever, P., Keech, A., Atar, D., Kurtz, C., Ruff, C. T., Mach, F., et al. (2022) · PLOS ONE

Lipoproteins and Cardiovascular HealthAlzheimer's disease research and treatments

Cited by 11